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Upon antigen recognition, naïve B cells undergo rapid proliferation followed by
differentiation to specialized antibody secreting cells (ASCs), called plasma cells.
Increased circulating plasma cells are reported in patients with B cell-associated
malignancies, chronic graft-vs.-host disease, and autoimmune disorders. Our aim was
to optimize an RNAi-based method that efficiently and reproducibly knocks-down
genes of interest in human primary peripheral B cells for the targeted analysis of ASC
differentiation. The unique contributions of transcriptional diversity in species-specific
regulatory networks and the mechanisms of gene function need to be approached
directly in human B cells with tools to hone our basic inferences from animal models
to human biology. To date, methods for gene knockdown in human primary B cells,
which tend to be more refractory to transfection than immortalized B cell lines, have
been limited by losses in cell viability and ineffective penetrance. Our single-step siRNA
nucleofector-based approach for human primary naïve B cells demonstrates reproducible
knockdown efficiency (∼40–60%). We focused on genes already known to play key
roles in murine ASC differentiation, such as interferon regulatory factor 4 (IRF4) and AID.
This study reports a validated non-viral method of siRNA delivery into human primary
B cells that can be applied to study gene regulatory networks that control human
ASC differentiation.
Keywords: IRF4, AID, siRNA knockdown, plasmablast, antibody secreting cells, B cell

INTRODUCTION
B lymphocytes are critical members of the adaptive immune system as they are uniquely
capable of secreting high titers of antigen-neutralizing antibody. B cells and their associated
antibody-mediated response to antigen are important in the clearance of viral, bacterial, and
fungal pathogens. Recognition of these foreign antigens by B cells triggers rapid proliferation and
differentiation to specialized antibody secreting cells (ASCs) known as plasma cells. The process
of ASC differentiation is a tightly regulated one that relies on synergistic signaling from multiple
pathways (1). A large gene-regulatory network of transcription factors is required for regulating
this multi-step process. One key player in the differentiation of naïve B cells to ASCs is the
transcription factor interferon regulatory factor 4 (IRF4). Its role in ASC differentiation has been
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well-characterized in mice (2–4). Expression of IRF4 is high in
murine ASCs and is critical for upregulating AID and BLIMP1
expression during ASC differentiation to plasma cells (5).
Very few of these murine-based B cell differentiation
studies, however, have been replicated in human primary
B cells. This delay in data replication is primarily due to
difficulties in achieving gene knockdown in human primary
naïve B cells, which tend to be more refractory to transfection
than immortalized B cell lines, and have been limited by
losses in cell viability and ineffective penetrance. While
genetic approaches in mice provide invaluable physiological
insights for identifying pathways which drive imbalance
of B cell subsets, the exclusive use of inbred mice with
limited diversity may mask pathways and gene functions
that exist uniquely in humans (6, 7). Thus, methods for
manipulating gene expression in human primary B cell subsets
is essential for transferring findings in mice to humans.
More importantly, an in vitro approach is necessary to
understand how gene dysregulation may contribute to the
development of human disease, including post-transplantation
systemic persistence of alloimmune and autoimmune responses
in chronic graft-vs.-host disease (8–14), as well as the severe
consequences of B cell dysfunction in indolently incurable or
aggressively fatal B cell-associated malignancies (15, 16), and
autoimmunity (17).
In peripheral blood mononuclear cells (PBMCs) isolated
from circulating blood, human naïve B cells constitute 0.7–4.9%
of leukocytes (18). The variable frequency among individual
donors and the refractory nature of primary naïve B cells to
gene modification, by lentiviral vector or RNA transfection,
have been limiting factors in the study of human ASC
differentiation. Gene silencing by transfecting cells with small
interfering RNA (siRNA) leads to the rapid degradation of
corresponding mRNA and reduced target protein expression.
Nucleofection is an electroporation technique that enables
efficient introduction of siRNAs into cells and detectable
silencing of target genes. Here, we describe an optimized
non-viral method for transient knockdown by siRNA delivery
into human primary naïve B cells for the study of key
genes regulating ASC differentiation and effector function. We
focused on genes already known to play a role in murine
ASC differentiation, such as IRF4 and AID. This method has
been optimized for efficient knockdown of four genes—IRF4,
IRF5, AID, and GAPD—with minimal effects on cell viability
and maximal effects on cell recovery and functional analysis
after nucleofection.

Peripheral blood mononuclear cells (PBMC) were isolated
by Ficoll [Corning, Manassas, VA, 25-072-CV] density
centrifugation from buffy coats purchased from the NY
Blood Center (Long Island City, NY). Naïve or total B cell
purifications was performed by negative selection with magnetic
separation according to manufacturer instructions (Stem Cell
Technologies, Vancouver, Canada) using EasySep Human naïve
B cell enrichment kit [19254] or naïve B cell isolation kit [17254].
Total B cell experiments were performed with cells purified using
EasySep Human total B cell enrichment kit [19054] to achieve
a >95% enriched population of naïve B cells (CD19+ IgD+ ) or
total B cells (CD19+ ). Isolated naïve B cells ranged from 5 × 106
to 26 × 106 from individual donor leukopaks containing 4 × 108
to 1 × 109 PBMCs.

Targeted siRNA Nucleofection
Isolated naïve B cells were centrifuged in antibiotic-free, serumcontaining media as recommended by the Amaxa P3 Primary
Cell 4D-Nucloefector X Kit L [Lonza, Cologne, Germany,
V4XP-3024] at 300 × g for 10 min at room temperature.
Cells were resuspended in room temperature Amaxa buffer as
suggested by the manufacturer for primary cells. 2–3 × 106
cells/100 µL cuvette was the final concentration of cells used
for nucleofection. For optimal results, siRNA was resuspended
in 1X siRNA buffer composed of 5X buffer [GE Lifesciences,
Lafayette, CO, B-002000-UB-100] diluted in nuclease-free
water [Ambion, USA, AM9938] and used for nucleofection
the same day. Reconstituted siRNA stored at −80◦ C for up
to 2–4 weeks will generally retain knockdown efficiency, as
determined by nucleofection and monitoring knockdown
efficiency over time (data not shown). B cells were nucleofected
with either mock (no siRNA), 1.5 µM of ON-TARGETplus
Non-targeting Control Pool [Dharmacon, Lafayette, CO,
D-001810-10-05] or SMARTpool ON-TARGETplus human
IRF4 siRNA [Dharmacon, LU-019668-00-0005]. 1–1.5 µM
ON-TARGETplus Targeted Control GAPD Pool [Dharmacon,
D-001830-10-05], 1–1.5 µM of ON-TARGETplus AICDA
siRNA [Dharmacon, LU-021409-00-0005], and 1.5 µM
siGLO green transfection indicator siRNA [Dharmacon, D001630-01-05] were also used. Cells were nucleofected using
program EO-117 for primary human B cells of the Amaxa 4D
Nucleofector system [Lonza] composed of the core unit and the
X unit.
Immediately after nucleofection, 500 µL of pre-warmed
(37◦ C) antibiotic-free media (10% fetal bovine serum (FBS) in
Iscove’s Modified Dulbecco’s Media (IMDM) without antibiotics)
was added to the cuvette by slowly releasing the media along the
wall of the cuvette. The final suspension was then transferred
into wells of a 24-well plate that each contained 1 mL of prewarmed antibiotic-free media [Sigma, USA, F4135] per cuvette
and cells allowed to rest in culture for 24 h at 37◦ C in 5% CO2 .
After resting, cells were transferred to a 14 mL Falcon tube to
be pelleted, counted and then cultured with the appropriate
cocktails for B cell activation or plasmablast differentiation.

MATERIALS AND METHODS
Ethics Statement
This study was carried out in accordance with the Declaration
of Helsinki. This study used blood from leukopaks of human
healthy donors purchased from the New York Blood Center.
These types of de-identified, publicly and commercially available
specimens are exempt from ethics approval as they are
fully anonymized.
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with unconjugated goat polyclonal primary antibody [Santa
Cruz Biotech., CA, sc-14680], and subsequently stained with
donkey anti-goat IgG-AF488 secondary [Invitrogen, USA, A11055]. Intracellular GAPD was stained with unconjugated
rabbit anti-human GAPDH antibody EPR16891 [Abcam, USA,
ab181602] and subsequently with goat anti-rabbit AF488 [Life
Technologies, A11034]. Intracellular IRF4 was detected with
rat anti-human/mouse IRF4-phycoerythrin (PE) [Biolegend,
646404] and rat immunoglobulin (Ig)G1, k isotype control
[Biolegend, 400408]. Cells staining positive for the live/dead stain
were excluded from the flow cytometry analysis. Doublets were
excluded from our analysis of FSC-A vs. FSC-H gating. Naïve
B cells were defined by CD19+ IgD+ surface expression, and
plasmablasts were defined by CD19+ CD20+ IgD− CD27+ CD38+
surface expression (Supplementary Figure 1). FCS files were
analyzed using FlowJo v9.3.2 (Tree Star Inc., Ashland, OR).

TABLE 1 | Antibodies used for surface staining and flow cytometry.
Surface marker

Fluorochrome

Clone

Company

Catalog

Live/dead

yellow

N/A

Invitrogen/thermofisher

L34968

Live/dead

green

N/A

Invitrogen/thermofisher

L34969

CD19

BV421

HIB19

Biolegend

302234

CD19

BV510

HIB19

Biolegend

302242

IgD

APC

IA6-2

Biolegend

348222

CD38

PE-CF594

HIT2

BD biosciences

562288

CD27

PE

M-T271

BD pharmigen

555441

Viability Post-nucleofection
Viability was determined by staining cells with trypan blue
[Life Technologies, Carlsbad, CA, 15250-061] after resting
nucleofected cells for 24 h and assessing by hemocytometer.
Percent viable was calculated using the equation 100 × (total
cells—blue cells)/total number.

Statistical Analysis
All statistical analyses were performed using Prism v6.2
(GraphPad Software, San Diego, CA). Student’s t-test was used
for comparisons between two samples with normal distribution.
Prior to test, graph kurtosis was analyzed to ensure normal
distribution. Data are reported as mean ± SEM. P-value < 0.05
was considered significant.

In vitro B Cell Activation and
Plasmablast Differentiation
After resting, nucleofected naïve B cells were cultured in
96-well U-bottom plates [Costar, USA, 3799] at a minimal
density of 0.5 × 106 in 250 µL of IMDM supplemented
with 10% FBS and 1X penicillin-streptomycin [Corning, 30002-Cl] per well. B cell cultures of 3 days or less were
treated with or without 10 µg/mL unconjugated goat antihuman IgM antibody [Southern Biotech, Birmingham, AL 202001] and 2.5 µg/mL CpG-B oligodeoxynucleotide (ODN) 2006
[Hycult Tech, Uden, The Netherlands, HC4309]. For plasmablast
differentiation, purified naïve B cells were cultured for 7 days
in the presence of 200 ng/mL sCD40L [Peprotech, Rocky Hill,
NJ 310-02-10UG] alone or a “C4” cocktail, consisting of
200 ng/mL sCD40L, 100 ng/mL IL-21 [Peprotech, 200-21-2UG],
10 µg/mL unconjugated goat anti-human IgM antibody, and
2.5 µg/mL CpG-B ODN 2006 (17, 19–24). For activation prior
to nucleofection, 2 × 106 cells/mL were stimulated in a 24-well
flat bottom plate overnight with or without CpG-B plus antiIgM in a final volume of 1 mL IMDM supplemented with 10%
FBS and penicillin-streptomycin. After pre-activation, cells were
washed twice with 0.5% BSA in 1 × PBS and counted for the
nucleofection protocol described above.

RESULTS
Analysis of Cell Viability After
Nucleofection and Optimization of Cell
Number for ASC Differentiation
We previously attempted shRNA lentiviral transduction of
human primary naïve B cells and were unsuccessful. We later
developed a siRNA nucleofection protocol that required two
rounds of nucleofection with low concentrations of IRF5 siRNAs
over 48 h to obtain ∼40–60% knockdown efficiency of IRF5
proteins in human primary naïve B cells (17). We have now
optimized the protocol further for single siRNA nucleofection
and knockdown of other genes involved in ASC differentiation
(Figure 1A). We initially optimized the protocol for IRF4
knockdown, as it is known to play essential roles in murine
ASC differentiation. In mice lacking Irf4, B and T cells were
unable to proliferate in response to B cell receptor (BCR), T cell
receptor (TCR), CD40, or LPS stimulation (25). Studies in mice
revealed that Irf4 is necessary for AID upregulation, class-switch
recombination (CSR), and generation of plasma cells in response
to BCR signaling (5, 26, 27).
Since primary B cells are notoriously difficult-to-transfect,
and we are interested in one of the more rare subsets, plasma
cells, we first optimized naïve B cell numbers and viability
after nucleofection for downstream analysis of plasma cells
by flow cytometry (17). In this assay, cells were either left
untouched, mock-nucleofected, or nucleofected with 1.5 µM
ON-TARGETplus Non-targeting Control (NTC) Pool siRNA. By
trypan blue staining, no significant difference in cell viability
was detected 24 h post-nucleofection of primary naïve B cells
(Figure 1B).

Flow Cytometry
B cells were washed with 1X PBS and stained with Live/Dead
Fixable Yellow Dead Cell Stain Kit viability discrimination dye
[Life Technologies, L34959]. Cells were subsequently blocked
in 2% bovine serum albumin (BSA) supplemented with human
TruStain FcX Blocker [Biolegend, San Diego, CA, 422302] for
5 min and then stained with antibodies against B cell surface
markers (Table 1). After staining, cells were washed in 1X PBS
and then fixed in 2% PFA before analysis on a BD Fortessa
flow cytometer [BD Biosciences]. For intracellular protein
staining, after overnight fixation, cells were permeabilized in
0.1% Triton X-100 and rinsed in 1X PBS 2 times before
blocking in 5% BSA solution. Intracellular AID was detected
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FIGURE 1 | RNAi knockdown in primary human naïve B cells by Amaxa nucleofection protocol. (A) Overview of nucleofection protocol and experimental readouts. (B)
Isolated human naïve B cells were nucleofected with or without non-targeting control (NTC) siRNA and rested for 24 h. Viability of cells after resting was determined by
trypan blue staining (n = 4). (C) Optimal seeding density of non-nucleofected primary human naïve B cells to generate plasmablasts in a 96-well plate via 7 day in vitro
culture with C4 cocktail (n = 4). (D) Same as (C) except optimal seeding density is shown for nucleofected cells (n = 4).

with 10% FBS and no antibiotics was added to each cuvette
and gently aspirated with pipettes provided in the kit for gentle
transfer of cells into wells of a 24-well plate that had been preequilibrated to 37◦ C at 5% CO2 with 1.0 mL of IMDM/well.
Cells were then rested for 24 h at 37◦ C in 5% CO2 . Cell loss
can occur at this point when transferring from the 24-well plate
to the tube for washing. To address this, wells were thoroughly
washed with 1 mL sterile 1X PBS or media using a 1,000 µL
pipette to physically detach cells along the bottom surface and the
circumference of the well. This step can be repeated as needed.
Distinct from non-nucleofected naïve B cells, we found that 0.5
× 106 cells per well of a 96-well plate were required for optimal
plasmablast generation after mock nucleofection (Figure 1D)
(17). Thus, a critical step in the process is to re-count your cells
after nucleofection and 24 h resting before transferring naïve B
cells to a 96-well plate for 7 day in vitro culture to plasmablasts
using the C4 cocktail. A good rule of thumb for calculating
cell number for downstream functional analysis is to begin with
nearly twice the number of cells that you want to end with for
functional analysis post-nucleofection.

A single leukopak of blood (∼35–38 mL) yields between 5
and 26 × 106 naïve B cells. To determine the appropriate
number of purified primary naïve B cells that will lead to
sufficient plasma cell numbers for functional analysis, we
examined differentiation of naïve B cells, at different seeding
densities, to plasmablasts by 7 day in vitro culture with C4
cocktail (anti-IgM, CpG-B, IL21, and CD40L) (17, 19–24, 28).
Similar to previously published work, in non-nucleofected naïve
B cells, a seeding density of 0.25 × 106 cells per well of
a 96-well plate was required for the optimal generation of
CD19+ IgD− CD27+ CD38+ plasmablasts (Figure 1C) (29, 30).
Representative gating strategy for plasmablasts is shown in
Supplementary Figure 1. As recommended by the manufacturer,
all Amaxa nucleofection reagents were kept at room temperature
prior to use. For primary naïve B cells, we found that an optimal
cell concentration for nucleofection with maximal siRNA entry
and cell viability post-nucleofection was 2–2.5 × 106 cells per
cuvette (in 100 µL volume); below 1.5 × 106 or above 3 × 106
million cells reduced viability and nucleofection efficiency. After
nucleofection, 500 µL of 37◦ C pre-warmed IMDM supplemented
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FIGURE 2 | IRF4 knockdown in primary human naïve B cells by Amaxa nucleofection protocol. Isolated human naive B cells were nucleofected with or without IRF4
targeting siRNA and stimulated with or without anti-IgM + CpG-B for 48 h. (A) Comparison of single vs. dual nucleofection protocols (n = 4). (B) Isolated human naive
B cells were nucleofected with or without 1.5 µM IRF4 targeting siRNA or non-targeting control (NTC) siRNA, rested for 24 h, and stimulated with or without anti-IgM
+ CpG-B for 48 h. Representative histogram overlays show IRF4 expression after stimulation. (C,D) Similar to B except data are summarized from multiple
independent experiments showing % IRF4+ CD19+ IgD+ B cells (C) and MFI of IRF4 in CD19+ IgD+ B cells (D) from n = 8 independent donors. Paired t-test for
significance was performed (*p < 0.05).

Analysis of Knockdown Efficiency and
ASC Differentiation

time points for analysis of IRF4 and AID protein expression after
knockdown. An a priori understanding of mRNA and protein
expression patterns of the particular gene of interest is required
to determine appropriate time points for knockdown analysis.
Although we previously found that efficient knockdown
of IRF5 in human primary naïve B cells required a dual
nucleofection protocol with low siRNA concentrations
(17), for IRF4, we were able to optimize knockdown by
single nucleofection of 1.5 µM siRNAs (Figure 2A). Using
the single nucleofection protocol, we examined IRF4
knockdown efficiency after single nucleofection with mock,
SMARTpool ON-TARGETplus human IRF4 siRNA or NTC
siRNA. Results revealed a range of 30–50% knockdown
of IRF4 proteins by IRF4 siRNA, and not NTC siRNA, at
72 h post-nucleofection (24 h rest plus 48 h stimulation)
(Figures 2B–D and Supplementary Figures 2C–F) with >95%

IRF4 expression is high in plasma cells and low in naïve B
cells but expression increases within 48 h after stimulation with
anti-IgM for BCR cross-linking or CD40L (31, 32). siRNAmediated knockdown of IRF4 has been previously described in
total CD19+ B cells using a final concentration of 1.5 µM siRNA
(33). We thus used IRF4 siRNAs in the range of 1–1.5 µM for
knockdown in human primary naïve B cells. Unlike IRF5 that
is expressed at sufficient basal levels in naïve B cells to detect
knockdown without stimulation (17), both IRF4 and AID are
expressed at very low levels and thus require B cell activation
to detect knockdown. We found that IRF4 expression peaked
at 48 h in CD19+ IgD+ B cells after stimulation of PBMC with
anti-IgM and the TLR9 agonist CpG-B; AID expression peaked
at 72–96 h (Supplementary Figures 2A,B). We thus used these
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FIGURE 3 | GAPD housekeeping gene as a positive control for nucleofection. (A) Representative figure showing histogram overlay of B cells nucleofected with 1 µM
GAPD siRNA and then cultured for 48 h post-nucleofection. (B) Paired dots show the efficiency of GAPDH knockdown in CD19+ IgD− B cells from matched
independent donors after 48 h culture (n = 6). (C) Same as (B) except IRF4 expression was determined after nucleofection with 1 µM GAPD siRNA (n = 6). (D) Naïve
B cells were cultured for 7 days with the C4 cocktail (anti-IgM + CpG-B + IL-21+ CD40L) to induce plasmablast differentiation post-nucleofection with 1.5 µM GAPD
siRNA, 1.5 µM IRF4 siRNA or 1.5 µM NTC siRNA. Plasmablast differentiation was determined by flow cytometry analysis of CD19+ IgD− CD27+ CD38+ cells (n = 9).
Bars represent mean ± SEM. (E) Correlation between % plasmablast reduction and % IRF4 MFI reduction. (F) Effect of GAPD siRNA on % plasmablasts from (D) are
shown as paired dots to indicate matched donor effects. Paired t-test for significance was performed (*p < 0.05).

viability (Supplementary Figure 3A). Notably, GAPD siRNA
also provided a Gaussian distribution of knockdown levels,
suggesting that all cells are getting nucleofected with siRNAs
equally. ASC differentiation was then examined after mocknucleofection, nucleofection with IRF4 siRNA, NTC siRNA,
or GAPD Targeted siRNA. Similar to findings in Irf4−/−
mice, knockdown of IRF4 in human primary naïve B cells
correlated with a significant reduction (∼30–40%) in ASC
differentiation (Figures 3D,E). While NTC siRNA had no
significant effect on plasmablast generation, we were surprised
to detect a strong trend in plasmablast reduction after GAPD
knockdown suggesting a potential role for GAPD in plasma cell
differentiation (Figures 3D,F). Indeed, GAPD is an important
regulator of cell growth, proliferation and survival due, in part,
to its role in regulating the generation of glycolytic ATP (35–
38). A subpopulation of naïve B cells, in response to B cell

post-nucleofection viability (Supplementary Figure 3A). Given
that IRF4 knockdown with IRF4 siRNAs gave a Gaussian
distribution of knockdown levels (Figure 2B), these data suggest
that all cells, rather than a small subset of cells, were nucleofected
with siRNA.
In addition to negative control siRNAs, positive control
siRNAs are recommended to confirm knockdown efficiency
and specificity of siRNA function (34). We utilized a positive
control siRNA targeting GAPD (ON-TARGETplus GAPD
Control Pool siRNA). All targeted and non-targeted siRNAs
were used at the same concentration for direct comparison
of effects (either 1 or 1.5 µM) (Supplementary Figure 3B).
Nucleofection with GAPD siRNAs resulted in a significant
reduction in GAPD protein at 72 h post-nucleofection (24 h
rest plus 48 h stimulation) (Figures 3A,B), with little significant
impact on IRF4 expression (Figure 3C) or post-nucleofection
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FIGURE 4 | Efficiency of AID knockdown in primary naïve human B cells is marginal at 48 and 72 h post-nucleofection. Isolated naïve B cells were stimulated with
anti-IgM + CpG-B after single nucleofection protocol with AID or GAPD siRNA (1 or 1.5 µM). (A) % AID+ CD19+ IgD+ B cells is shown at 48 h post-stimulation. (B)
AID MFI is shown at same time point as (A). (C) Same as (A) except % AID+ CD19+ IgD+ B cells is shown 72 h post-stimulation. (D) AID MFI is shown at same time
point as (C). Bars represent mean ± SEM (n = 4). Paired t-test for significance was performed (*p < 0.05).

activation, will survive and undergo clonal expansion, CSR and
differentiation to ASCs, in which GAPD has been implicated
in Migliaccio et al. (39). Thus, while positive control siRNAs
can serve as important tools for determining specificity of
function, they can also complicate the system, depending on the
downstream assays used to determine functional consequence(s)
of siRNA knockdown. Nonetheless, data clearly show that
the single nucleofection protocol can be used to knockdown
IRF4 efficiently, leading to a significant reduction in human
ASC differentiation.

ASC differentiation (40, 41). After titration, we identified
the optimal concentration of 1–1.5µM AICDA siRNA that
provided a significant, albeit, small reduction in the percentage
of CD19+ IgD+ AID+ B cells (∼10–20%) after anti-IgM +
CpG-B stimulation for 48 h (Figure 4A). Somewhat surprising,
this reduction did not translate into a significant reduction
in AID MFI (Figure 4B). Based on AID expression kinetics
(Supplementary Figure 2B), we extended the activation time
point to 72 h and were still unable to detect significant effects on
AID expression (Figures 4C,D).
Due to the low level of AID knockdown observed, we
examined an alternate approach to achieve more robust
knockdown of AID expression for functional analysis. We
hypothesized that the inherent characteristics of the gene
might require activation prior to nucleofection. Thus, purified
naïve B cells were activated first with anti-IgM and CpGB overnight prior to the standard nucleofection protocol and

Applying the Single Nucleofection
Knockdown Protocol to Other Genes
Involved in ASC Differentiation
To determine whether this method is effective for silencing other
genes that are induced after B cell activation, we examined
knockdown of AID, a factor that is critical for CSR during
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FIGURE 5 | Pre-activation of primary naïve human B cells enhances the effect of AID knockdown. Isolated naïve B cells were cultured for 24 h (+Pre-activation) or
without (-Pre-activation) anti-IgM + CpG-B then nucleofected one time with AID or NTC siRNA (1.5 µM). After 24 h resting, cells were re-stimulated with or without
anti-IgM + CpG-B for 72 h. (A) Representative histogram overlay of AID expression after knockdown in the presence or absence of pre-activation. (B) AID MFI in
CD19+ IgD+ B cells was determined at 72 h post-stimulation (n = 7). (C) Paired dots show the efficiency of AID knockdown in CD19+ IgD− B cells from matched
independent donors in (B). (D) Following pre-activation and nucleofection with AID or NTC siRNA, cells were in vitro cultured for 7 days with C4 cocktail to induce
plasmablast differentiation (CD19+ IgD− CD27+ CD38+ ) (n = 4). (E) Effect of AID siRNA on % plasmablasts from (D) are shown as paired dots to indicate matched
donor effects. Bars represent mean ± SEM. P-values were determined by paired t-test for significance (*p < 0.05).

AID siRNAs showed a more disparate level of knockdown
distribution. Given that gene expression can vary based on
cellular context resulting in unequal knockdown effects,
we attempted to optimize a method of co-nucleofection
for sorting and functional analysis of nucleofected cells
with knockdown.
We previously explored co-nucleofection of IRF5 siRNA
with GFP mRNA (Trinity Biotech: L601) or pmaxGFPTM vector
(Lonza) as a method to sort for cells with knockdown (17).
Unfortunately, we were unsuccessful as co-nucleofection with
GFP mRNA resulted in ∼20% GFP+ naïve B cells with no
correlation between GFP and IRF5 knockdown; both GFP+
and GFP− cells showed equivalent IRF5 knockdown levels (17).
Similarly, the pmaxGFPTM resulted in a low yield of GFP+
cells with only ∼2–4% of naïve B cells expressing GFP (17).
At the time, we hypothesized that the failed attempts might
be due to size restrictions on B cell uptake; green fluorescent
protein (GFP) is larger than most siRNAs. Here, we attempted

re-stimulation. Indeed, we detected a stronger knockdown effect
after pre-activation (Figure 5A), revealing that 1.5 µM AICDA
siRNA provides a significant reduction in AID MFI (ranging
from ∼30–50% knockdown) (Figures 5B,C). This level of AID
knockdown resulted in ∼90% loss of plasmablast differentiation
(Figures 5D,E), with no significant effect on cell viability
(Supplementary Figure 3A). Altogether, these data indicate that
the single nucleofection protocol for knockdown in human
primary naïve B cells can be applied to multiple genes.

Sorting of Knockdown Cells by
Co-nucleofection With siGLO
It was previously reported that the abundance of target
gene expression is a critical factor that determines the
efficiency of siRNA-mediated gene silencing (42). IRF4
and GAPD siRNAs showed a Gaussian distribution
of knockdown levels suggesting that most cells were
nucleofected equally with siRNAs (Figures 2B, 3A), while
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FIGURE 6 | siGLO green nucleofection of purified primary naïve B is transient and lost by 48 h post-nucleofection. (A) Representative dot plots showing purified naïve
B cells nucleofected with 1.5 µM siGLO or 1.5 µM siGLO + 1.5 µM IRF4 siRNA cultured for 24, 48, and 72 h after nucleofection and analyzed for siGLO+ cells. (B)
Similar to (A) except representative histograms show the different siGLO co-nucleofection efficiencies in naïve B cells at 24 h post-nucleofection. (C) % siGLO+ B cells
are shown from multiple independent experiments of (B) at 24 h post-nucleofection (n = 5). (D) IRF4 knockdown effect is retained in naïve B cells co-nucleofected
with siGLO and IRF4 siRNA after stimulation with anti-IgM + CpG-B for 48 h (n = 4). (E) Same as (D) except GAPD MFI was examined 24 h post-nucleofection
(n = 3). (F) Comparison of GAPD knockdown from (E) in siGLO+ vs. siGLO− cells. Bars represent mean ± SEM. P-values were determined by paired t-test for
significance (*p < 0.05, **p < 0.01).

post-nucleofection. We detected similar siGLO nucleofection
efficiency as seen before (∼10–30%, Supplementary Figure 4A)
and knockdown of GAPD was retained independent of siGLO
(Figure 6E). Importantly, while the overall nucleofection
efficiency was low with siGLO (Supplementary Figure 4B),
data in Figure 6F suggest that knockdown of genes with
abundant baseline expression (Supplementary Figure 4C)
may be tracked with siGLO since we detected ∼40%
reduction of GAPD protein levels in siGLO+ cells at 24 h
post-nucleofection.
We next attempted co-nucleofection of total CD19+ B cells
with siGLO and IRF4 siRNA to examine nucleofection efficiency
and knockdown in multiple B cell subsets at one time. We
detected similar but low levels of siGLO in both naïve B cells and
plasmablasts 24 h post-nucleofection (Figures 7A–C). Analysis
of IRF4 knockdown in naïve B cells revealed a similar knockdown
level as that seen by nucleofection of purified naïve B cells
(Figures 2, 7D) suggesting that this may be an alternate method
for knockdown in naïve B cells. However, depending on the

a new strategy for knockdown and selection using Dharmacon’s
siGLO green reagent that is used to examine siRNA transfection
efficiency. Primary naïve B cells were co-nucleofected with
equal parts of IRF4 siRNA and siGLO green. After 24 and 48 h
post-nucleofection, nucleofecion efficiency and IRF4 knockdown
were examined by flow cytometry. We detected a range in siGLO
nucleofection efficiency with 10 to 45% of cells being siGLO+ ;
similar levels were seen in co-nucleofected cells (Figures 6A–C).
Importantly, IRF4 knockdown levels were similar between conucleofected and IRF4 siRNA nucleofected samples (Figure 6D)
suggesting that siGLO does not compete with IRF4 for entry
into cells during nucleofection. Unfortunately though, we found
that the siGLO signal dramatically decreases, independent of
concentration, 24 h post-nucleofection (Figure 6A), which
is before we are able to detect significant IRF4 knockdown
(Figure 2). Thus, to further assess the use of siGLO for
tracking nucleofection with knockdown, we co-nucleofected
cells with siGLO and NTC siRNA or GAPD siRNA and
performed the similar analysis at the earlier time point of 24 h
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FIGURE 7 | Efficiency of siGLO co-nucleofection with IRF4 siRNA in purified total CD19+ human B cells. (A) Representative dot plots of gated naïve B cells
(CD19+ IgD+ ) and plasmablasts (CD19+ IgD− CD27+ CD38+ ) that are siGLO+ at 24 h post-nucleofection with 1.5 µM siGLO. (B,C) Similar to (A) except data are
summarized from multiple independent experiments showing siGLO nucleofection efficiency at 24 and 72 h post-nucleofection in naïve B cells (B) and plasmablasts
(C) (n = 4). (D) IRF4 knockdown efficiency is retained in naïve B cells and plasmablasts after co-nucleofection of total B cells with siGLO and stimulation with anti-IgM
+ CpG-B for 48 h (n = 4). Bars represent mean ± SEM. P-values were determined by paired t-test for significance (*p < 0.05).

concentrations likely minimize activation of RNA sensors and
genes regulating the inflammatory response, which ultimately
lead to IRF5 upregulation (48–50). In the case of IRF4, we were
unable to detect knockdown after dual nucleofection with low
concentrations of siRNA (Figure 2A). Dual nucleofection also
results in more cell loss due to two transfer steps from cuvette
to plate (data not shown). Further, genes such as IRF4 and AID
that are expressed at low levels in naïve B cells require stimulation
with a B cell activating trigger in order to detect knockdown.
While optimizing our protocol for AID, we found that preactivation was necessary to enhance the effect of knockdown.
Similarly, other examples exist for genes with distinct patterns
of expression in B cell differentiation, such as BACH2 (51), that
requires alternate nucleofection protocols. Thus, the variation in
knockdown efficiency between genes and amongst methods to
determine knockdown efficiency (MFI vs. percent positivity) may
be attributed to the inherent variation in gene expression (42).
Despite the limited and variable quantity of starting material,
combined with the limited recovery of cells post-nucleofection,
the bulk study of transient gene knockdown in human primary
naïve B cells by flow cytometry after nucleofection can be

experimental outcome, sorting naïve B cells from nucleofected
total B cells is unlikely to yield sufficient cell number for
downstream functional analysis. Last, significant knockdown of
IRF4 in plasmablasts was detected also by this method.

DISCUSSION
In this report, we describe an optimized method for RNAi
nucleofection of human primary naïve B cells to study the role
of genes, such as IRF4 and AID that contribute to human
ASC differentiation. The knockdown efficiency of both IRF4
and AID was sufficient to observe downstream functional effects
on plasmablast differentiation. The central issue in optimizing
gene knockdown, however, is to understand basal expression
and expression induced after stimulation of your target gene.
For transcription factors such as IRF5 that are sensitive to
activation by nucleic acid-sensing innate immune sensors (43–
47), we suggest optimizing with the low dose dual nucleofection
protocol described by De et al. (17). Low concentrations of
siRNA (500 nM), in two sequential nucleofections, provided an
IRF5 knockdown with 40–60% efficiency (17). The lower siRNA
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FIGURE 8 | Schematic summarizing an optimized method for RNAi knockdown in primary human naïve B cells.

achieved with the methods described herein (Figure 8). The
optimal cell density of nucleofected naïve B cells when cultured
long-term for plasmablast differentiation (7 days) was 5 × 105
after nucleofection. This number is likely necessary due to cellcell contact required by B cells. Thus, key features of our method
take into account cell density at the point of nucleofection
and after nucleofection, as well as the kinetics of the target
protein expression.
A good starting point for knocking down any gene of
interest is to begin with 1 µM of siRNA; however, this may
require further optimization depending on the kinetics of gene
expression. Data presented herein suggests that knockdown in
other B cell subsets can be obtained by nucleofection of total B
cells, followed by sorting subsets of interest (Figure 7). However,
some subsets, such as memory B cells and plasma cells that
are low in the circulation will require alternative methods (52)
for knockdown. For human primary GC plasma cells, Maarof
et al. (53) describe a method for isolation and nucleofection
to study IL-24 cytokine expression. Additional methods have

Frontiers in Immunology | www.frontiersin.org

been developed to study pre-B cells (54). Whether the general
approach we describe can be applied to studies in patient
samples is dependent on the specific considerations regarding
amount of starting material available and relative frequency of
the cell type being studied (55–58). Thus, depending on the
cell subset of interest and functional read-out, methods may
need to be further optimized to take into account reduced
cell numbers.
Unfortunately, 100% transfection efficiency was not achieved
in our study or by others (17, 51–54), possibly due to stochastic
kinetics of siRNA entry into primary B cells (59). As death of
primary human B cells following nucleofection correlates with
size and structure of nucleic acids being transfected (60), siRNA
knockdown efficiencies may vary between siRNAs and gene
targets (61). Further, nucleofection of human B cells has been
reported to be relatively inefficient when compared to human
T cells (52). And, few, if any, studies have reported siRNA
knockdown in human primary naïve B cells (17, 51). Applications
of new technologies for genome editing, such as CRISPR-CAS9,
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